Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2019, Article ID 3012509, 14 pages
https://doi.org/10.1155/2019/3012509
Review Article

Cardiovascular Manifestations of Inflammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies

1Department of Cardiology, Institute of Cardiovascular Diseases, Timisoara 300310, Romania
2Department of Radiology, County Emergency Hospital Timisoara, Timisoara 300723, Romania
3Department of Pathophysiology, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi 700111, Romania
4Department of Internal Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi 700111, Romania
53rd Internal Medicine Clinic, “Sf. Spiridon” County Clinical Emergency Hospital Iasi, Iasi, Romania
6Department of Morpho-Functional Sciences I, Discipline of Anatomy, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, Iasi 700111, Romania
7Institute of Gastroenterology and Hepatology-“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Iasi, Romania
8“Grigore T. Popa” University of Medicine and Pharmacy, Iasi 700111, Romania

Correspondence should be addressed to Cristian-Eugen Timofte; moc.duolci@etfomit.naitsirc and Mariana Floria; moc.oohay@anairam_airolf

Received 2 September 2018; Revised 18 November 2018; Accepted 6 December 2018; Published 13 January 2019

Academic Editor: Konstantinos Triantafyllou

Copyright © 2019 Diana-Maria Bunu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Kilcoyne, J. L. Kaplan, and M. S. Gee, “Inflammatory bowel disease imaging: current practice and future directions,” World Journal of Gastroenterology, vol. 22, no. 3, pp. 917–932, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. A. N. Aslan, C. Sarı, S. Özer Sarı et al., “Association between aortic stiffness and left ventricular function in inflammatory bowel disease,” Cardiology Journal, vol. 23, no. 2, pp. 202–210, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. H. S. P. de Souza and C. Fiocchi, “Immunopathogenesis of IBD: current state of the art,” Nature Reviews Gastroenterology & Hepatology, vol. 13, no. 1, pp. 13–27, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. M. F. Neurath, “Cytokines in inflammatory bowel disease,” Nature Reviews Immunology, vol. 14, no. 5, pp. 329–342, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Coskun, S. Vermeire, and O. H. Nielsen, “Novel targeted therapies for inflammatory bowel disease,” Trends in Pharmacological Sciences, vol. 38, no. 2, pp. 127–142, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Nathan and A. Ding, “Nonresolving inflammation,” Cell, vol. 140, no. 6, pp. 871–882, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. H. J. Su, Y. T. Chiu, C. T. Chiu et al., “Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates,” Journal of the Formosan Medical Association, 2018. View at Publisher · View at Google Scholar
  8. J. D. Olpin, B. P. Sjoberg, S. E. Stilwill, L. E. Jensen, M. Rezvani, and A. M. Shaaban, “Beyond the bowel: extraintestinal manifestations of inflammatory bowel disease,” Radiographics, vol. 37, no. 4, pp. 1135–1160, 2017. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Karmiris, A. Avgerinos, A. Tavernaraki et al., “Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 10, no. 4, pp. 429–436, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Vizzardi, E. Sciatti, I. Bonadei et al., “Subclinical cardiac involvement in Crohn’s disease and ulcerative colitis: an echocardiographic case-control study,” Panminerva Medica, vol. 58, no. 2, pp. 115–120, 2016. View at Google Scholar
  11. S. R. Vavricka, A. Schoepfer, M. Scharl, P. L. Lakatos, A. Navarini, and G. Rogler, “Extraintestinal manifestations of inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 21, no. 8, pp. 1982–1992, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Harbord, V. Annese, S. R. Vavricka et al., “The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 10, no. 3, pp. 239–254, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Aarestrup, T. Jess, C. J. Kobylecki, B. G. Nordestgaard, and K. H. Allin, “Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of more than 100000 individuals,” Journal of Crohn's and Colitis, 2018. View at Publisher · View at Google Scholar
  14. T. R. Card, S. M. Langan, and T. P. C. Chu, “Extra-gastrointestinal manifestations of inflammatory bowel disease may be less common than previously reported,” Digestive Diseases and Sciences, vol. 61, no. 9, pp. 2619–2626, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. N. E. Mitchell, N. Harrison, Z. Junga, and M. Singla, “Heart under attack: cardiac manifestations of inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 24, no. 11, pp. 2322–2326, 2018. View at Publisher · View at Google Scholar · View at Scopus
  16. K. H. Katsanos and E. V. Tsianos, “The heart in inflammatory bowel disease,” Annals of Gastroenterology, vol. 15, no. 2, pp. 124–133, 2002. View at Google Scholar
  17. E. H. Park, B. J. Kim, J. K. Huh et al., “Recurrent mesalazine-induced myopericarditis in a patient with ulcerative colitis,” Journal of Cardiovascular Ultrasound, vol. 20, no. 3, pp. 154–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. H. T. Sørensen and K. M. Fonager, “Myocarditis and inflammatory bowel disease. A 16-year Danish nationwide cohort study,” Danish Medical Bulletin, vol. 44, no. 4, pp. 442–444, 1997. View at Google Scholar
  19. V. P. Tan, A. Chung, B. P. Yan, and P. R. Gibson, “Venous and arterial disease in inflammatory bowel disease,” Journal of Gastroenterology and Hepatology, vol. 28, no. 7, pp. 1095–1113, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Alatri, A. Schoepfer, N. Fournier et al., “Prevalence and risk factors for venous thromboembolic complications in the Swiss inflammatory bowel disease cohort,” Scandinavian Journal of Gastroenterology, vol. 51, no. 10, pp. 1200–1205, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Bollen, N. Vande Casteele, M. Peeters et al., “The occurrence of thrombosis in inflammatory bowel disease is reflected in the clot lysis profile,” Inflammatory Bowel Diseases, vol. 21, no. 11, pp. 2540–2548, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Zezos, G. Kouklakis, and F. Saibil, “Inflammatory bowel disease and thromboembolism,” World Journal of Gastroenterology, vol. 20, no. 38, pp. 13863–13878, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Singh, H. Singh, E. V. Loftus Jr., and D. S. Pardi, “Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis,” Clinical Gastroenterology and Hepatology, vol. 12, no. 3, pp. 382–393.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. S. L. Kristensen, O. Ahlehoff, J. Lindhardsen et al., “Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death – a Danish nationwide cohort study,” PLoS One, vol. 8, no. 2, p. e56944, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. W. Feng, G. Chen, D. Cai, S. Zhao, J. Cheng, and H. Shen, “Inflammatory bowel disease and risk of ischemic heart disease: an updated meta‐analysis of cohort studies,” Journal of the American Heart Association, vol. 6, no. 8, article e005892, 2017. View at Publisher · View at Google Scholar · View at Scopus
  26. A. H. Katsanos, M. Kosmidou, S. Giannopoulos et al., “Cerebral arterial infarction in inflammatory bowel diseases,” European Journal of Internal Medicine, vol. 25, no. 1, pp. 37–44, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. T.-Y. Lin, Y.-G. Chen, C.-L. Lin, W.-S. Huang, and C.-H. Kao, “Inflammatory bowel disease increases the risk of peripheral arterial disease: a nationwide cohort study,” Medicine, vol. 94, no. 52, p. e2381, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Agüero, G. González-Zobl, J. M. Baena-Díez et al., “Prevalence of lower extremity peripheral arterial disease in individuals with chronic immune mediated inflammatory disorders,” Atherosclerosis, vol. 242, no. 1, pp. 1–7, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. I. E. Koutroubakis, “Therapy insight: vascular complications in patients with inflammatory bowel disease,” Nature Clinical Practice Gastroenterology & Hepatology, vol. 2, no. 6, pp. 266–272, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Aniwan, D. S. Pardi, W. J. Tremaine, and E. V. Loftus Jr, “Increased risk of acute myocardial infarction and heart failure in patients with inflammatory bowel diseases,” Clinical Gastroenterology and Hepatology, vol. 16, no. 10, pp. 1607–1615.e1, 2018. View at Publisher · View at Google Scholar · View at Scopus
  31. S. L. Kristensen, O. Ahlehoff, J. Lindhardsen et al., “Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure: a Danish nationwide cohort study,” Circulation: Heart Failure, vol. 7, no. 5, pp. 717–722, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. D. J. Pattanshetty, K. Anna, R. D. Gajulapalli, and R. S. R. Sappati-Biyyani, “Inflammatory bowel “cardiac” disease: point prevalence of atrial fibrillation in inflammatory bowel disease population,” Saudi Journal of Gastroenterology, vol. 21, no. 5, pp. 325–329, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. S. L. Kristensen, J. Lindhardsen, O. Ahlehoff et al., “Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study,” Europace, vol. 16, no. 4, pp. 477–484, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. T. H. Efe, T. Cimen, A. G. Ertem et al., “Atrial electromechanical properties in inflammatory bowel disease,” Echocardiography, vol. 33, no. 9, pp. 1309–1316, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Berkelhammer, J. Andrejic, and A. Mohammed, “Endocarditis in Crohn’s disease,” Inflammatory Bowel Diseases, vol. 15, no. 9, pp. 1293-1294, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Kreuzpaintner, D. Horstkotte, A. Heyll, B. Lösse, and G. Strohmeyer, “Increased risk of bacterial endocarditis in inflammatory bowel disease,” The American Journal of Medicine, vol. 92, no. 4, pp. 391–395, 1992. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Bragagni, R. Brogna, P. Franceschetti, and G. Zoli, “Cardiac involvement in Crohn’s disease: echocardiographic study,” Journal of Gastroenterology and Hepatology, vol. 22, no. 1, pp. 18–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Kusunoki, S. Ishihara, M. Sato et al., “Rare case of Takayasu’s arteritis associated with Crohn’s disease,” Internal Medicine, vol. 50, no. 15, pp. 1581–1585, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Le Mener, S. Huynh-Moynot, J. A. Bronstein, U. Vinsonneau, and Z. Richert, “Les myocardites aiguës compliquant les maladies inflammatoires chroniques de l’intestin : à propos de deux observations,” La Revue de Médecine Interne, vol. 33, no. 10, pp. 583–585, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. A. L. P. Caforio, S. Pankuweit, E. Arbustini et al., “Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases,” European Heart Journal, vol. 34, no. 33, pp. 2636–2648, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Asadi, S. S. Bhandari, and N. Ahmed, “Mesalazine-induced myopericarditis in a patient with ulcerative colitis,” Echo Research and Practice, vol. 5, no. 1, pp. K1–K5, 2017. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Dominguez, U. Kühl, B. Pieske, P. Garcia-Pavia, and C. Tschöpe, “Update on myocarditis and inflammatory cardiomyopathy: reemergence of endomyocardial biopsy,” Revista Española de Cardiología, vol. 69, no. 2, pp. 178–187, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. W. Bracamonte-Baran and D. Čiháková, “Cardiac autoimmunity: myocarditis,” Advances in Experimental Medicine and Biology, vol. 1003, pp. 187–221, 2017. View at Publisher · View at Google Scholar · View at Scopus
  44. G. Brown, “5-Aminosalicylic acid-associated myocarditis and pericarditis: a narrative review,” The Canadian Journal of Hospital Pharmacy, vol. 69, no. 6, pp. 466–472, 2016. View at Google Scholar
  45. M. Moonen and P. Lancellotti, “La myocardite,” Revue Médicale de Liège, vol. 73, no. 5-6, pp. 269–276, 2018. View at Google Scholar
  46. I. Kindermann, C. Barth, F. Mahfoud et al., “Update on myocarditis,” Journal of the American College of Cardiology, vol. 59, no. 9, pp. 779–792, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. V. C. Varnavas, N. Reinsch, M. Perrey et al., “Recurrent lymphocytic myocarditis in a young male with ulcerative colitis,” European Journal of Medical Research, vol. 19, no. 1, p. 11, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. L. T. Cooper, K. L. Baughman, A. M. Feldman et al., “The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology,” Journal of the American College of Cardiology, vol. 50, no. 19, pp. 1914–1931, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Ponikowski, A. A. Voors, S. D. Anker et al., “2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure,” European Journal of Heart Failure, vol. 18, no. 8, pp. 891–975, 2016. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Klein and R. Eliakim, “Non steroidal anti-inflammatory drugs and inflammatory bowel disease,” Pharmaceuticals (Basel), vol. 3, no. 4, pp. 1084–1092, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. H. P. Schultheiss, U. Kühl, and L. T. Cooper, “The management of myocarditis,” European Heart Journal, vol. 32, no. 21, pp. 2616–2625, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Van Assche, A. Dignass, B. Bokemeyer et al., “Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations,” Journal of Crohn's and Colitis, vol. 7, no. 1, pp. 1–33, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Giannotta, G. Tapete, G. Emmi, E. Silvestri, and M. Milla, “Thrombosis in inflammatory bowel diseases: what’s the link?” Thrombosis Journal, vol. 13, no. 1, p. 14, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. D. Kohoutova, P. Moravkova, P. Kruzliak, and J. Bures, “Thromboembolic complications in inflammatory bowel disease,” Journal of Thrombosis and Thrombolysis, vol. 39, no. 4, pp. 489–498, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. V. F. Tapson, “Acute pulmonary embolism,” The New England Journal of Medicine, vol. 358, no. 10, pp. 1037–1052, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Owczarek, D. Cibor, M. K. Głowacki, T. Rodacki, and T. Mach, “Inflammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability,” World Journal of Gastroenterology, vol. 20, no. 1, pp. 53–63, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Schicho, G. Marsche, and M. Storr, “Cardiovascular complications in inflammatory bowel disease,” Current Drug Targets, vol. 16, no. 3, pp. 181–188, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Scaldaferri, S. Lancellotti, M. Pizzoferrato, and R. De Cristofaro, “Haemostatic system in inflammatory bowel diseases: new players in gut inflammation,” World Journal of Gastroenterology, vol. 17, no. 5, pp. 594–608, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Danese, C. de la Motte, and C. Fiocchi, “Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications,” The American Journal of Gastroenterology, vol. 99, no. 5, pp. 938–945, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. O. A. Hatoum and D. G. Binion, “The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology,” Inflammatory Bowel Diseases, vol. 11, no. 3, pp. 304–313, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. N. Chande, “Prevention of venous thromboembolism in hospitalized patients with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 19, no. 3, pp. 669–671, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Alhassan, A. Pelinescu, V. Gandhi, M. Naddour, A. C. Singh, and E. Bihler, “Clinical presentation and risk factors of venous thromboembolic disease,” Critical Care Nursing Quarterly, vol. 40, no. 3, pp. 201–209, 2017. View at Publisher · View at Google Scholar · View at Scopus
  63. P. Papay, W. Miehsler, H. Tilg et al., “Clinical presentation of venous thromboembolism in inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 7, no. 9, pp. 723–729, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. G. C. Nguyen, C. N. Bernstein, A. Bitton et al., “Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian association of gastroenterology,” Gastroenterology, vol. 146, no. 3, pp. 835–848.e6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. W. H. Geerts, D. Bergqvist, G. F. Pineo et al., “Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition),” Chest Journal, vol. 133, Supplement, no. 6, pp. 381S–453S, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. N. L. Zitomersky, M. Verhave, and C. C. Trenor III, “Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention,” Inflammatory Bowel Diseases, vol. 17, no. 1, pp. 458–470, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. C. Rungoe, N. Nyboe Andersen, and T. Jess, “Inflammatory bowel disease and risk of coronary heart disease,” Trends in Cardiovascular Medicine, vol. 25, no. 8, pp. 699–704, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. A. J. Yarur, A. R. Deshpande, D. M. Pechman, L. Tamariz, M. T. Abreu, and D. A. Sussman, “Inflammatory bowel disease is associated with an increased incidence of cardiovascular events,” The American Journal of Gastroenterology, vol. 106, no. 4, pp. 741–747, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. A. B. Reiss, N. M. Siegart, and J. De Leon, “Interleukin-6 in atherosclerosis: atherogenic or atheroprotective?” Clinical Lipidology, vol. 12, no. 1, pp. 14–23, 2017. View at Google Scholar
  70. J. W. Harper and T. L. Zisman, “Interaction of obesity and inflammatory bowel disease,” World Journal of Gastroenterology, vol. 22, no. 35, pp. 7868–7881, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. I. D'Odorico, S. di Bella, J. Monticelli, D. R. Giacobbe, E. Boldock, and R. Luzzati, “Role of fecal microbiota transplantation in inflammatory bowel disease,” Journal of Digestive Diseases, vol. 19, no. 6, pp. 322–334, 2018. View at Publisher · View at Google Scholar · View at Scopus
  72. C. Manichanh, N. Borruel, F. Casellas, and F. Guarner, “The gut microbiota in IBD,” Nature Reviews Gastroenterology & Hepatology, vol. 9, no. 10, pp. 599–608, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Wilson, W. A. Teft, B. L. Morse et al., “Erratum to: trimethylamine-N-oxide: a novel biomarker for the identification of inflammatory bowel disease,” Digestive Diseases and Sciences, vol. 61, no. 1, p. 325, 2016. View at Publisher · View at Google Scholar · View at Scopus
  74. W. H. W. Tang, D. Y. Li, and S. L. Hazen, “Dietary metabolism, the gut microbiome, and heart failure,” Nature Reviews Cardiology, 2018. View at Publisher · View at Google Scholar
  75. P. Kruzliak, J. Novák, M. Novák, and G. J. Fodor, “Role of calprotectin in cardiometabolic diseases,” Cytokine & Growth Factor Reviews, vol. 25, no. 1, pp. 67–75, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. L. Zanoli, S. Rastelli, A. Granata et al., “Arterial stiffness in inflammatory bowel disease: a systematic review and meta-analysis,” Journal of Hypertension, vol. 34, no. 5, pp. 822–829, 2016. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Galluzzo, G. Patti, G. Dicuonzo et al., “Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study,” Human Immunology, vol. 72, no. 8, pp. 636–640, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. R. S. R. Sappati Biyyani, B. S. Putka, and K. D. Mullen, “Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease,” Journal of Clinical Lipidology, vol. 4, no. 6, pp. 478–482, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Pak, J. Linares, Y. Yatsynovich et al., “Spontaneous ventricular thrombosis in patients with inflammatory bowel disease,” Cardiology in the Young, vol. 28, no. 3, pp. 351–353, 2018. View at Publisher · View at Google Scholar · View at Scopus
  80. W. J. Powers, A. A. Rabinstein, T. Ackerson et al., “2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association,” Stroke, vol. 49, no. 3, pp. e46–e110, 2018. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Ibanez, S. James, S. Agewall et al., “2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC),” European Heart Journal, vol. 39, no. 2, pp. 119–177, 2018. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Bala, J. Kashuk, E. E. Moore et al., “Acute mesenteric ischemia: guidelines of the World Society of Emergency Surgery,” World Journal of Emergency Surgery, vol. 12, no. 1, p. 38, 2017. View at Publisher · View at Google Scholar · View at Scopus
  83. K. H. Katsanos, D. K. Christodoulou, K. Pappas, C. Pappas, and E. V. Tsianos, “Electrocardiograph abnormalities in patients with active inflammatory bowel disease,” Annals of Gastroenterology, vol. 20, no. 4, pp. 275–281, 2007. View at Google Scholar
  84. M. De Simone, U. Cioffi, E. Contessini-Avesani et al., “Elevated serum procollagen type III peptide in splanchnic and peripheral circulation of patients with inflammatory bowel disease submitted to surgery,” BMC Gastroenterology, vol. 4, no. 1, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. O. A. Hatoum, D. G. Binion, M. F. Otterson, and D. D. Gutterman, “Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation,” Gastroenterology, vol. 125, no. 1, pp. 58–69, 2003. View at Publisher · View at Google Scholar · View at Scopus
  86. D. Waśko-Czopnik and L. Paradowski, “The influence of deficiencies of essential trace elements and vitamins on the course of Crohn’s disease,” Advances in Clinical and Experimental Medicine, vol. 21, no. 1, pp. 5–11, 2012. View at Google Scholar
  87. A. Cincin, M. Sunbul, T. Kivrak et al., “Evaluation of cardiac function by two-dimensional speckle tracking echocardiography in ulcerative colitis patients,” Digestive Diseases and Sciences, vol. 59, no. 12, pp. 3004–3011, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. T. Kivrak, M. Sunbul, A. Cincin et al., “Two-dimensional speckle tracking echocardiography is useful in early detection of left ventricular impairment in patients with Crohn’s disease,” European Review for Medical and Pharmacological Sciences, vol. 20, no. 15, pp. 3249–3254, 2016. View at Google Scholar
  89. K. O. Hensel, F. E. Abellan Schneyder, L. Wilke, A. Heusch, S. Wirth, and A. C. Jenke, “Speckle tracking stress echocardiography uncovers early subclinical cardiac involvement in pediatric patients with inflammatory bowel diseases,” Scientific Reports, vol. 7, no. 1, p. 2966, 2017. View at Publisher · View at Google Scholar · View at Scopus
  90. S. F. Nagueh, O. A. Smiseth, C. P. Appleton et al., “Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging,” Journal of the American Society of Echocardiography, vol. 29, no. 4, pp. 277–314, 2016. View at Publisher · View at Google Scholar · View at Scopus
  91. O. Gedikli, A. Dogan, I. Altuntas et al., “Inflammatory markers according to types of atrial fibrillation,” International Journal of Cardiology, vol. 120, no. 2, pp. 193–197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. H. A. Bornaun, N. Yılmaz, G. Kutluk et al., “Prolonged P-wave and QT dispersion in children with inflammatory bowel disease in remission,” BioMed Research International, vol. 2017, Article ID 6960810, 7 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  93. A. R. M. Sridhar, S. Parasa, U. Navaneethan, M. D. Crowell, and K. Olden, “Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients,” Journal of Crohn's and Colitis, vol. 5, no. 4, pp. 287–294, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. D. J. Pattanshetty, R. D. Gajulapalli, K. Anna, and R. S. S. Biyyani, “Prevalence of QT interval prolongation in inflammatory bowel disease,” The Turkish Journal of Gastroenterology, vol. 27, no. 2, pp. 136–142, 2016. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Engel, S. Ben-Horin, and M. Beer-Gabel, “Autonomic dysfunction correlates with clinical and inflammatory activity in patients with Crohn’s disease,” Inflammatory Bowel Diseases, vol. 21, no. 10, pp. 2320–2326, 2015. View at Publisher · View at Google Scholar · View at Scopus
  96. Y. Dogan, A. Soylu, G. A. Eren et al., “Evaluation of QT and P wave dispersion and mean platelet volume among inflammatory bowel disease patients,” International Journal of Medical Sciences, vol. 8, no. 7, pp. 540–546, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. G. Nar, B. Ergul, G. Aksan, and S. Inci, “Assessment of atrial electromechanical delay and left atrial mechanical functions in patients with ulcerative colitis,” Echocardiography, vol. 33, no. 7, pp. 970–976, 2016. View at Publisher · View at Google Scholar · View at Scopus
  98. T. T. Issac, H. Dokainish, and N. M. Lakkis, “Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data,” Journal of the American College of Cardiology, vol. 50, no. 21, pp. 2021–2028, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. C. P. Anand, A. Al-Juburi, and B. Sandeep, “Heart block occurring during infliximab infusion: a report of two cases,” The American Journal of Gastroenterology, vol. 98, no. 9, p. S144, 2003. View at Publisher · View at Google Scholar
  100. M. Curione, M. Barbato, S. Amato et al., “Atrioventricular block associated with Crohn’s relapsing colitis in a 12-year-old child,” Inflammatory Bowel Diseases, vol. 16, no. 3, pp. 373-374, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Gesualdo, P. Scicchitano, S. Carbonara et al., “The association between cardiac and gastrointestinal disorders: causal or casual link?” Journal of Cardiovascular Medicine, vol. 17, no. 5, pp. 330–338, 2016. View at Publisher · View at Google Scholar · View at Scopus
  102. P. M. Seferović, A. D. Ristić, R. Maksimović et al., “Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases,” Rheumatology, vol. 45, Supplement_4, pp. iv39–iv42, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. U. Nussinovitch, J. Freire de Carvalho, R. M. R. Pereira, and Y. Shoenfeld, “Glucocorticoids and the cardiovascular system: state of the art,” Current Pharmaceutical Design, vol. 16, no. 32, pp. 3574–3585, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. P. Eickhoff, T. Fazekas, A. Attarbaschi, and T. Binder, “Mitral valve endocarditis caused by ulcerative colitis followed by septic embolic occlusion of the superior mesenteric artery,” European Journal of Echocardiography, vol. 10, no. 6, pp. 806-807, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Singh, V. Goyal, P. Padhi, and E. Aoun, “Bacteroides fragilis endocarditis in a patient with Crohn’s disease,” Case Reports, vol. 2013, article bcr2013009248, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. W. Uchida, M. Mutsuga, H. Ito, H. Oshima, and A. Usui, “Nonbacterial thrombotic endocarditis associated with Crohn disease,” The Annals of Thoracic Surgery, vol. 105, no. 5, pp. e199–e201, 2018. View at Publisher · View at Google Scholar · View at Scopus
  107. G. Habib, P. Lancellotti, M. J. Antunes et al., “2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM),” European Heart Journal, vol. 36, no. 44, pp. 3075–3128, 2015. View at Publisher · View at Google Scholar · View at Scopus
  108. R. Giacomo, T. Gianluca, T. Luca, and C. Maurizio, “A severe but predictable complication of an inflammatory bowel disease,” World Journal of Cardiovascular Surgery, vol. 3, no. 5, pp. 129-130, 2013. View at Publisher · View at Google Scholar
  109. D. R. Ramsdale, T. S. J. Elliott, P. Wright et al., “Guidance on the prophylaxis and treatment of infective endocarditis in adults,” http://www.bcs.com/restricted/registered/affiliates/endocarditis_guidance.pdf.
  110. D. Lacey and P. Bouillet, “Deregulation of TNF expression can also cause heart valve disease,” Cytokine, vol. 77, pp. 248-249, 2016. View at Publisher · View at Google Scholar · View at Scopus
  111. K. A. LaBresh, E. V. Lally, S. C. Sharma, and G. Ho Jr, “Two-dimensional echocardiographic detection of preclinical aortic root abnormalities in rheumatoid variant diseases,” The American Journal of Medicine, vol. 78, no. 6, pp. 908–912, 1985. View at Publisher · View at Google Scholar · View at Scopus
  112. I. Ozsöyler, L. Yilik, S. Bozok, C. Ozbek, and A. Gürbüz, “Cardiovascular involvement in Crohn’s disease in the absence of ankylosing spondylitis,” Heart and Vessels, vol. 20, no. 4, pp. 164–166, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. M. E. Evangelopoulos, S. Toumanidis, D. Sotou et al., “Mitral valve prolapse in young healthy individuals. An early index of autoimmunity?” Lupus, vol. 18, no. 5, pp. 436–440, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. N. Minami, H. Nakase, T. Yoshino et al., “Effect of infliximab on inflammatory bowel disease with Takayasu arteritis: case series and review of the literature,” Clinical Journal of Gastroenterology, vol. 6, no. 3, pp. 226–230, 2013. View at Publisher · View at Google Scholar · View at Scopus
  115. S. Akiyama, T. Fujii, K. Matsuoka et al., “Endoscopic features and genetic background of inflammatory bowel disease complicated with Takayasu arteritis,” Journal of Gastroenterology and Hepatology, vol. 32, no. 5, pp. 1011–1017, 2017. View at Publisher · View at Google Scholar · View at Scopus
  116. E. Seyahi, “Takayasu arteritis: an update,” Current Opinion in Rheumatology, vol. 29, no. 1, pp. 51–56, 2017. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Isobe, “Takayasu arteritis revisited: current diagnosis and treatment,” International Journal of Cardiology, vol. 168, no. 1, pp. 3–10, 2013. View at Publisher · View at Google Scholar · View at Scopus
  118. A. Sy, N. Khalidi, N. Dehghan et al., “Vasculitis in patients with inflammatory bowel diseases: a study of 32 patients and systematic review of the literature,” Seminars in Arthritis and Rheumatism, vol. 45, no. 4, pp. 475–482, 2016. View at Publisher · View at Google Scholar · View at Scopus
  119. A. B. Pithadia and S. Jain, “Treatment of inflammatory bowel disease (IBD),” Pharmacological Reports, vol. 63, no. 3, pp. 629–642, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. J. F. Jackson and S. V. Sitaraman, “Pericarditis as the presenting sign of Crohn’s disease,” Inflammatory Bowel Diseases, vol. 11, no. 1, pp. 81-82, 2005. View at Publisher · View at Google Scholar · View at Scopus
  121. S. Asirvatham, C. Sebastian, and U. Thadani, “Severe symptomatic sinus bradycardia associated with mesalamine use,” American Journal of Gastroenterology, vol. 93, no. 3, pp. 470-471, 1998. View at Publisher · View at Google Scholar · View at Scopus
  122. H. Schacke, W. D. Döcke, and K. Asadullah, “Mechanisms involved in the side effects of glucocorticoids,” Pharmacology & Therapeutics, vol. 96, no. 1, pp. 23–43, 2002. View at Publisher · View at Google Scholar · View at Scopus
  123. J. N. Hoes, J. W. G. Jacobs, S. M. M. Verstappen, J. W. J. Bijlsma, and G. J. M. G. van der Heijden, “Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis,” Annals of the Rheumatic Diseases, vol. 68, no. 12, pp. 1833–1838, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. R. M. Stanbury and E. M. Graham, “Systemic corticosteroid therapy—side effects and their management,” British Journal of Ophthalmology, vol. 82, no. 6, pp. 704–708, 1998. View at Publisher · View at Google Scholar · View at Scopus
  125. L. Wei, T. M. MacDonald, and B. R. Walker, “Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease,” Annals of Internal Medicine, vol. 141, no. 10, pp. 764–770, 2004. View at Publisher · View at Google Scholar · View at Scopus
  126. P. Welsh, G. Grassia, S. Botha, N. Sattar, and P. Maffia, “Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?” British Journal of Pharmacology, vol. 174, no. 22, pp. 3898–3913, 2017. View at Publisher · View at Google Scholar · View at Scopus
  127. P. Dogan, E. Grbovic, S. Inci, F. Bayraktar, and K. Cagli, “Azathioprine-induced atrial fibrillation,” Intractable & Rare Diseases Research, vol. 4, no. 4, pp. 207–209, 2015. View at Publisher · View at Google Scholar · View at Scopus
  128. A. Cassinotti, A. Massari, E. Ferrara et al., “New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature,” European Journal of Clinical Pharmacology, vol. 63, no. 9, pp. 875–878, 2007. View at Publisher · View at Google Scholar · View at Scopus
  129. A. Yuri Gasparyan, L. Ayvazyan, G. Cocco, and G. D. Kitas, “Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research,” Current Pharmaceutical Design, vol. 18, no. 11, pp. 1543–1555, 2012. View at Publisher · View at Google Scholar
  130. G. Demirtaş-Ertan, A. T. Rowshani, and I. J. ten Berge, “Azathioprine-induced shock in a patient suffering from undifferentiated erosive oligoarthritis,” The Netherlands Journal of Medicine, vol. 64, no. 4, pp. 124–126, 2006. View at Google Scholar
  131. https://www.drugs.com/sfx/methotrexate-side-effects.html 2018 November.
  132. P. E. Lazzerini, P. L. Capecchi, M. Galeazzi, and F. Laghi-Pasini, “Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad,” Immunologic Research, vol. 65, no. 1, pp. 262–275, 2017. View at Publisher · View at Google Scholar · View at Scopus
  133. W. Miehsler, G. Novacek, H. Wenzl et al., “A decade of infliximab: the Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 4, no. 3, pp. 221–256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  134. L. Tomáš, I. Lazúrová, L. Pundová et al., “Acute and long-term effect of infliximab on humoral and echocardiographic parameters in patients with chronic inflammatory diseases,” Clinical Rheumatology, vol. 32, no. 1, pp. 61–66, 2013. View at Publisher · View at Google Scholar · View at Scopus
  135. L. Zanoli, S. Rastelli, G. Inserra et al., “Increased arterial stiffness in inflammatory bowel diseases is dependent upon inflammation and reduced by immunomodulatory drugs,” Atherosclerosis, vol. 234, no. 2, pp. 346–351, 2014. View at Publisher · View at Google Scholar · View at Scopus
  136. S. D. Thapa, H. Hadid, W. Imam, J. Schairer, and S. M. Jafri, “Effect of inflammatory bowel disease-related characteristics and treatment interventions on cardiovascular disease incidence,” The American Journal of the Medical Sciences, vol. 350, no. 3, pp. 175–180, 2015. View at Publisher · View at Google Scholar · View at Scopus
  137. M. Zuin, G. Rigatelli, G. del Favero et al., “Cardiovascular disease in patients with inflammatory bowel disease: an issue in no guidelines land,” International Journal of Cardiology, vol. 222, pp. 984-985, 2016. View at Publisher · View at Google Scholar · View at Scopus
  138. H. H. Sun and F. Tian, “Inflammatory bowel disease and cardiovascular disease incidence and mortality: a meta-analysis,” European Journal of Preventive Cardiology, vol. 25, no. 15, pp. 1623–1631, 2018. View at Publisher · View at Google Scholar · View at Scopus